| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JTK10; JAK2 |
| Entrez GeneID | 3717 |
| clone | 1C1 |
| WB Predicted band size | 130.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of JAK2(745-955aa) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
1. **《JAK2 mutations in myeloproliferative disorders》**
- 作者：Baxter EJ, et al.
- 摘要：该研究首次报道JAK2 V617F突变在骨髓增殖性疾病(如真性红细胞增多症)中的高频率，并开发了一种基于抗体的检测方法，用于识别突变蛋白的表达，为疾病诊断提供了新工具。
2. **《The JAK2 V617F mutation is a rare event in healthy individuals》**
- 作者：Tefferi A, et al.
- 摘要：通过Western blot和免疫组化分析健康人群与患者的JAK2蛋白表达，发现V617F突变在健康人中极罕见，验证了JAK2抗体在临床鉴别诊断中的特异性及潜在价值。
3. **《Comparison of molecular and antibody-based assays for detection of JAK2 mutations》**
- 作者：Kralovics R, et al.
- 摘要：对比PCR测序与抗JAK2抗体(如抗pJAK2)的检测效能，显示抗体法在筛查突变患者时灵敏度较高，但需结合分子方法确认，尤其适用于初筛和动态监测。
4. **《JAK2 inhibition as a therapeutic strategy in myelofibrosis》**
- 作者：Verstovsek S, et al.
- 摘要：探讨针对JAK2通路的抗体及小分子抑制剂在骨髓纤维化治疗中的作用，证明抑制JAK2信号可改善症状，并强调抗体工具在靶向机制研究中的重要性。
The Janus kinase 2 (JAK2) protein is a tyrosine kinase critical for signaling pathways regulating hematopoiesis, immune function, and cell growth. Antibodies targeting JAK2 are primarily used in research and diagnostics to detect JAK2 expression or mutations, notably the V617F mutation. This gain-of-function mutation, located in the pseudokinase domain, causes constitutive activation of JAK2 and downstream signaling (e.g., STAT, MAPK), leading to uncontrolled cell proliferation. It is strongly associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
JAK2 antibodies are essential tools for identifying this mutation via techniques like ELISA, immunohistochemistry (IHC), or Western blot. In clinical settings, detecting JAK2 V617F (present in >95% of polycythemia vera cases) aids in diagnosing and classifying MPNs, differentiating them from reactive conditions. Other JAK2 mutations (e.g., exon 12 mutations) are also linked to MPNs, expanding the utility of these antibodies.
Beyond diagnostics, JAK2 antibodies contribute to studying disease mechanisms and evaluating JAK inhibitors (e.g., ruxolitinib) in preclinical models. However, cross-reactivity with other JAK family members (JAK1. JAK3. TYK2) requires careful antibody validation. Overall, JAK2 antibodies play a pivotal role in advancing both the understanding and management of hematologic disorders driven by dysregulated JAK-STAT signaling.
×
